cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD
cAMPfield Therapeutics, Inc. announced its official launch alongside the completion of a $180 million Series...
Insight, China's Pharmaceutical Industry
Fineline Insights, Pharma Clarity